Learn more about whether Haemonetics Corporation or UFP Technologies, Inc. is a better investment based on AAII's A+ Investor ...

Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a research note on Friday, November 8th.

Would you like to be notified of the latest news and updates on the stock market?

Haemonetics Corporation provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. The company’s portfolio of ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Haemonetics Corp. (Symbol: HAE) entered into oversold territory, hitting an RSI reading of ...

Haemonetics Corporation (NYSE:HAE), a global healthcare company with a market capitalization of $3.48 billion, has seen its stock price touch a 52-week low, reaching $69.2. According to InvestingPro ...

Raymond James analyst Andrew Cooper maintained a Buy rating on Revvity (RVTY – Research Report) today and set a price target of $145.00. The ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

In a report released today, Joanne Wuensch from Citi maintained a Hold rating on Haemonetics (HAE – Research Report). The company’s shares closed yesterday at $75.05. Discover outperforming ...

BOSTON, Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes ...